Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether 500 mg Glucosamine Sulfate / 400 mg Chondroitin Sulfate Capsules and 1500 mg Glucosamine Sulfate / 1200 mg Chondroitin Sulfate Sachet is effective and safe compared Cosamin DS ® Capsule in Treatment of Knee Osteoarthritis.
The Groups receive treatment for 16 weeks. The study is realized in 16 sites in Brazil.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| glucosamine sulfate /chondroitin sulfate capsule | Experimental | 500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily. |
|
| glucosamine sulfate /chondroitin sulfate - sachet | Experimental | 1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily. |
|
| Cosamin DS® | Active Comparator | 500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| glucosamine sulfate /chondroitin sulfate - capsules | Drug | 500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in pain intensity in the affected knee and variation of Lequesne's index and VAS at week 16 . | BASELINE, week 16 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants with any Decrease in Pain Visual Analogue Scale (VAS) | baseline, week 16 |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants with Serious and Non-Serious Adverse Events | baseline, week 16 |
Inclusion Criteria:
Male or female patient, older than 40 years of age, with knee osteoarthritis, based on clinical and radiological criteria (Kellgren-Lawrence grade 2 - 3), as specified:
Knee osteoarthritis symptoms for at least six months prior to randomization.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| José R Provenza, MD | Pontifícia Universidade Católica de Campinas, São Paulo, Brazil | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Serviço de reumatologia do hospital e maternidade celso pierro da PUC-Campinas | Campinas | São Paulo | 13330-260 | Brazil |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| glucosamine sulfate /chondroitin sulfate - sachet | Drug | 1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily. |
|
| Cosamin DS® | Drug | 500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily. |
|
| ID | Term |
|---|---|
| D020370 | Osteoarthritis, Knee |
| ID | Term |
|---|---|
| D010003 | Osteoarthritis |
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D005944 | Glucosamine |
| D002809 | Chondroitin Sulfates |
| ID | Term |
|---|---|
| D006595 | Hexosamines |
| D000606 | Amino Sugars |
| D002241 | Carbohydrates |
| D002807 | Chondroitin |
| D006025 | Glycosaminoglycans |
| D011134 | Polysaccharides |
Not provided
Not provided